
    
      This study is a double-blind, double-dummy, randomized, placebo- and active-controlled,
      multicenter, parallel-group study of adult subjects with a primary clinical diagnosis of
      COPD. Approximately 800 subjects were to be randomized in this study. Study participation
      consisted of a total of eight (8) study visits over approximately four (4) months for each
      subject. This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was
      acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed
      to Sunovion Pharmaceuticals Inc.
    
  